Fundraising Fox株式会社モダリス
Tokyo, JP · 5 known investors
Find your way into 株式会社モダリス
Sign up to see every warm intro you have to 株式会社モダリス
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 株式会社モダリス team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.
Founders & leadership
HM
Haruhiko Morita代表取締役CEO (President & CEO)
Investors · 5
SMBC Venture Capitallisted by SMBC Venture CapitalTokyovia Hiroya Ota · inferred
How we know: SMBC Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Related companies · 4
TrisaluslifesciTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
GradalisGradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
Chrysalis BiotherapeuticsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as 株式会社モダリス.
Frequently asked questions
- What does 株式会社モダリス do?
- Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.
- Who founded 株式会社モダリス?
- 株式会社モダリス was founded by Haruhiko Morita.
- Who are 株式会社モダリス's investors?
- 株式会社モダリス's investors include Medical Incubator Japan K.K., Nippon Venture Capital, Shinsei Capital Partners, SMBC Venture Capital, UTokyo Innovation Platform Co. Ltd..
- Where is 株式会社モダリス headquartered?
- 株式会社モダリス is headquartered in Tokyo, JP.